What is MAIA Biotechnology Financial Strength?
MAIA Biotechnology has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
MAIA Biotechnology has no long-term debt (1).
As of today, MAIA Biotechnology's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of MAIA Biotechnology's Financial Strength
For the Biotechnology subindustry, MAIA Biotechnology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MAIA Biotechnology's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's Financial Strength distribution charts can be found below:
* The bar in red indicates where MAIA Biotechnology's Financial Strength falls into.
MAIA Biotechnology Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
MAIA Biotechnology's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-3.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
MAIA Biotechnology's Interest Coverage for the quarter that ended in Mar. 2024 is
| MAIA Biotechnology had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
MAIA Biotechnology's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
MAIA Biotechnology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAIA Biotechnology (MAIA Biotechnology) Business Description
Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
| Ramiro Guerrero |
director |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Cristian Luput |
director |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Vlad Vitoc |
director, 10 percent owner, officer: Chief Executive Officer |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Joseph F Mcguire |
officer: Chief Financial Officer |
6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656 |
| Stan Smith |
director |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Ngar Yee Louie |
director, 10 percent owner |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Jean-manasse Theagene |
director |
500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2 |
| Steven M Chaouki |
director |
C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661 |
| Sergei Gryaznov |
officer: Chief Scientific Officer |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Laurentiu Vlad |
director |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
| Mihail Obrocea |
officer: Chief Medical Officer |
444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606 |
MAIA Biotechnology (MAIA Biotechnology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MAIA has been successfully added to your